Overview
Inflection Medicine provides a hospital software platform for NICUs that blends genomic data, clinical information, and care plans inside the hospital’s electronic health record. It supports neonatal precision medicine by turning complex data from genomes, patient records, and family history into actionable, evidence-based guidance within NICU workflows. The product helps clinicians diagnose and treat critically ill newborns faster, reduce unnecessary tests, shorten hospital stays, and improve resource use. The system learns from prior cases to refine recommendations over time and supports long-term follow-up after discharge. Its customers are hospitals and clinical teams with NICUs who seek to improve newborn outcomes while lowering care costs.
Work here?Claim your company
Simplify's take
What believers are saying
- JAMA published Inflection-linked neonatal genomics evidence on September 28, 2026.
- Inflection joined the Health Care Transformation Task Force on August 13, 2026, boosting credibility.
- Hospitals can request demos now, and Inflection says deployment starts in six weeks.
What critics are saying
- Public fundraising shows only $100,000 in May 2026, signaling fragile commercialization capacity.
- BuiltInNYC listed five employees in October 2026, leaving sales, support, and integrations underpowered.
- If major hospital systems decline adoption, Inflection lacks scale to survive the NICU procurement cycle.
What makes Inflection Medicine unique
- Inflection Medicine embeds genomic decision support directly inside NICU EHR workflows.
- Its platform claims bedside deployment within six weeks, faster than typical hospital software cycles.
- The company’s clinical evidence center links JAMA 2026 neonatal genomics research to product claims.
Help us improve and share your feedback! Did you find this helpful?